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Abstract— DNA Methylation has been the most extensively studied 
epigenetic mark. Usually a change in the genotype, DNA sequence, 
leads to a change in the phenotype, observable characteristics of the 
individual. But DNA methylation, which happens in the context of 
CpG (cytosine and guanine bases linked by phosphate backbone) 
dinucleotides, does not lead to a change in the original DNA 
sequence, but has the potential to change the phenotype. DNA 
methylation is implicated in various biological processes and diseases 
including cancer. Hence there is a strong interest in understanding 
the DNA methylation patterns across various epigenetic related 
ailments in order to distinguish and diagnose the type of disease in its 
early stages. In this work, the relationship between methylated versus 
unmethylated CpG regions and cancer types is explored using 
Convolutional Neural Networks (CNNs). A CNN based Deep 
Learning model that can classify the cancer of a new DNA 
methylation profile based on the learning from publicly available 
DNA methylation datasets is then proposed. 
 
I. INTRODUCTION 
 
DNA Methylation is a chemical modification that refers to the 
addition of a Methyl group ( CH3) via a covalent bond to the C-5 
position of the Cytosine ring of DNA through a special class of 
enzymes called DNA Methyl Transferases (DNMTs) [1]. In 
humans, DNA Methylation occurs in the context of CpG 
dinucleotide sequence in somatic cells [2]. Exceptions to 
Methylation in context of CpG islands is observed in germline cells 
[3]. In human somatic cells most of the CpGs are Methylated. 
Unmethylated CpG regions are usually present at heads of the 
promoters in human genes, referred to as CpG islands [4][5]. 
 
Many techniques have been engineered over the past couple of 
decades to measure Methylated cytosines (5-mC). These techniques 
can vary from heat-based [6] to chemical-based methods [7][8]. 
Widely popular used technique to de-tect 5-mC is Bisulfite 
conversion technique used for preparing DNA for Methylation 
analysis on a gene-specific level[9]. In this technique unmethylated 
Cytosine is converted to Uracil while leaving 5-mC base intact to 
allow Methylation analysis at a single-nucleotide resolution. 
 
DNA Methylation regulates many biological processes such as 
cell differentiation, development, cell reprogramming and 
proliferation through modulation of gene expression [10][11][12]. 
More studies on DNA Methylation revealed Differentially 
Methylated Regions (DMRs) that are DNA sequences that have  
 
 
 
 
 
 
 
 
 
 
 
varying Methylation profiles between different tissues, cell-lines, 
stages of development and organ-isms. Studying these regions are 
of immense interest in order to understand how differing 
Methylation profiles between biological samples can have an 
impact on implementing tissue-specific gene regulatory expression 
profiles [13].  
Aberrant DMR patterns have been implicated in many diseases 
including autoimmune disorders [14], metabolic disorders [15], 
psychological disorders [16], aging [17] and cancer [18]. Therefore, 
quantifying the differences in DNA methylation across large 
numbers of samples and the identification of sample-specificity are 
critical steps in genomic function analysis, in normal and disease 
conditions.  
Various studies on DNA methylation in the past have shown a 
strong link between differential DNA methylation and it’s effects 
on regulating gene expression [19] [20]. Existing methods 
summarize differential methylation patterns localized for certain 
DNA regions which limits the scope of analysis. This study pushes 
the limits of analysis to a global scale through learning of changing 
DMR patterns and distinguishing them between different cancer 
types at a whole-genome level. This approach has immense 
potential to accurately diagnose the condition and even the stage of 
the disease. Based on this premise experiments were performed 
using high-throughput DNA methylation profiles from genome-
wide analysis of various cancer types to classify them based on the 
learning of their DMR regions. This study utilized extensive DNA 
methylation data from The Cancer Genome Atlas (TCGA) 
repository [20], the details for which have been provided in the next 
section.  
While there have been attempts at classifying diseases based on 
DNA methylation beta-values [21] [22], none have used a datasets 
and the choice of cutting-edge models as extensive and varied as 
the ones used in this work. The experiments carried out in this 
study involved training a Convolutional Neural Network (CNN) 
based Deep Learning classifier [23] on large volumes of publicly 
available DNA Methylation data obtained from high-throughput 
Bisulfite Sequencing methods, on cancer sub-types in order to 
create a representation of the differences between various cancer 
profiles. 
 
II. DATA 
 
For this study, cancer datasets were chosen due to the wealth of 
information available in The Cancer Genome Atlas 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Visualization of DNA methylation data of two different diseases transformed into images.   
DNA Methylation profile data of individual samples, each transformed into an image of dimensions 220 x 1663. Each pixel value corresponds to the beta-
value of a single CpG site. These images served as the input to train the proposed model. 
A) Transformed image of BLCA - Urothelial Bladder Carcinoma 
B) Transformed image of PRAD - Prostate Adenocarcinoma 
 
 
(TCGA). The TCGA is a comprehensive archive of tumoral data 
containing the results of high-throughout experiments, mainly Next 
Generation Sequencing, for more than 30 cancer types [24]. TCGA 
contains 2.5 petabytes of whole-genome data that is made free 
available to the public and used widely by independent researchers 
contributing to thousands of studies on cancer. DNA methylation 
data was extracted using the TCGA2BED tool [25]. It contained 
DNA Methylation profiles from 33 different cancer types.  
The data extracts from TCGA were samples that were processed 
to level 3 data type, which has the whole genome methylation calls 
for each CpG site, per sample in a tab-delimited file (.bed). All the 
DNA methylation profiles used in our experiment were aligned 
with the reference genome GRCh37 (hg19) [26]. About 10,000 
DNA methylation pro-files encompassing 33 different cancer types 
were extracted from the TCGA. Data obtained from Illumina 450k 
DNA methylation samples were taken for our experiments. The 
detailed list is provided in Table I. 
 
III. DATA PREPROCESSING 
 
The beta-value is a metric that corresponds to the ratio of 
intensities between the methylated probe and the overall intensity 
(sum of the methylated and unmethylated probes). This value 
ranges between 0 and 1, meaning that under ideal conditions the 
corresponding CpG region is either entirely unmethylated or totally 
methylated respectively [27].  
Normalization is a technique used to scale input values to the 
neural network to a smaller range. This reduces training time and 
variance in the training loss graph. Since the Methylation values are 
already in between the values of 0 and 1, normalization is not done.  
Null values are replaced with zeros. While there are 33 different 
cancer diseases present in the dataset, training is not done with 
Ovarian Cancer (OV) DNA Methylation data as it was under 
represented (only 11 samples) in the dataset.  
The data was divided into 3 parts: 20% of the data is used for 
testing and out of the remaining 80%, 10% is used as a validation 
set and the rest is used for training. 
There are 365860 rows (each row corresponds to information on 
a CpG site) for each sample across all the cancer types. The beta-
value of the corresponding row are extracted and converted into a 
matrix of shape (220; 1663). Each value in the matrix is defined by 
the beta-value (ranging from 0 to 1) of that CpG site. This matrix is 
given as an input image to the CNN model (described in the next 
section). Some of these images are presented in figure 1. 
 
IV. MODEL 
 
Various CNN architectures were tested with different filter 
shapes that can properly find the relationship between the different 
DNA Methylation patterns that are thought to be correlated with 
diseases.  
The model that is used is similar to that used by Yoon Kim for 
sentence classification [28]. The input to the model is an image, 
 
x  Rhw (1)  
where h and w are the height and width of the image.  
Convolutional operation with two filter shapes are used: 
 
w1  Rkw (2) 
  
TABLE I  
LIST OF CANCER TYPES AND NUMBER OF SAMPLES USED IN OUR STUDY 
 
Tumor Tag Tumor Name Experiment # Aliquot # Samples # Patients 
acc Adrenocortical carcinoma dnamethylation450 81 81 81 
blca Bladder Urothelial Carcinoma dnamethylation450 464 439 414 
brca Breast Invasive carcinoma dnamethylation450 930 897 794 
cesc Cervical squamous cell carcinoma and endocervical adenocarcinoma dnamethylation450 331 314 309 
chol Cholangiocarcinoma dnamethylation450 46 46 37 
coad Colon adenocarcinoma dnamethylation450 367 350 299 
dlbc Lymphoid Neoplasm Diffuse Large B-cell Lymphoma dnamethylation450 53 50 50 
esca Esophageal carcinoma dnamethylation450 212 204 187 
gbm Glioblastoma multiforme dnamethylation450 162 156 143 
hnsc Head and Neck squamous cell carcinoma dnamethylation450 598 582 530 
kich Kidney Chromophobe dnamethylation450 67 67 67 
kirc Kidney renal clear cell carcinoma dnamethylation450 496 485 321 
kirp Kidney renal papillary cell carcinoma dnamethylation450 336 323 277 
laml Acute Myeloid Leukemia dnamethylation450 194 194 194 
lgg Brain Lower Grade Glioma dnamethylation450 551 536 518 
lihc Liver hepatocellular carcinoma dnamethylation450 450 432 379 
luad Lung adenocarcinoma dnamethylation450 525 505 463 
lusc Lung squamous cell carcinoma dnamethylation450 413 408 371 
meso Mesothelioma dnamethylation450 89 88 88 
paad Pancreatic adenocarcinoma dnamethylation450 207 197 186 
pcpg Pheochromocytoma and Paraganglioma dnamethylation450 189 188 180 
prad Prostate adenocarcinoma dnamethylation450 573 555 500 
read Rectum adenocarcinoma dnamethylation450 113 108 100 
sarc Sarcoma dnamethylation450 285 271 263 
skcm Skin Cutaneous Melanoma dnamethylation450 493 478 473 
stad Stomach adenocarcinoma dnamethylation450 413 400 398 
tgct Testicular Germ Cell Tumors dnamethylation450 158 157 151 
thca Thyroid carcinoma dnamethylation450 588 573 509 
thym Thymoma dnamethylation450 128 127 125 
ucec Uterine Corpus Endometrial Carcinoma dnamethylation450 508 484 446 
ucs Uterine Carcinosarcoma dnamethylation450 58 58 58 
uvm Uveal Melanoma dnamethylation450 81 81 81 
  Total 10,159 9,834 8,992  
 
 
 
w2  R
hk 
(3)  
where k is the window size used to produce a new feature. 
The filters are applied successively to get an output feature 
map for that filter. While filter w1 is applied along the height 
of the image, filter w2 searches for features along the width 
of the image. Unlike the model proposed by Yoon Kim in 
[28], a max pooling operation is not performed on the 
feature maps obtained. Instead all the features of the output 
feature map are retained.  
The model has a single filter layer with multiple such fil-
ters with variable window sizes to extract numerous features. 
The filters are grouped into four types with five filters in 
each type based on the window size of the filter. 
While all the w1 convolutional filters have the same width 
(equal to the width of the image), their heights are 1, 3, 5 and 
7. Whereas all the w2 convolutional filters have the same 
height (equal to the height of the image) and their widths are 
1, 3, 5 or 7.  
The ideology behind such a filter shape is to allow the 
narrow filter to learn the smaller or local features whereas 
the wider filters will be able to learn larger features that are 
more spread out over different DNA methylation regions. 
After the filter layer, all the features are concatenated. 
This concatenated output is then fed into two fully connected 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Model Architecture 
 
 
 
 
 
 
layers. These layers have 512 and 128 neurons followed by a 
softmax layer with 32 neurons for each of the classes. The model 
architecture has been illustrated in figure 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. Accuracy vs Epochs Fig. 4. Loss vs Epochs 
 
 
A. Model Training 
 
Training was done using mini batch stochastic gradient descent 
(SGD) using shuffled mini batches of size 30. Adam optimizer with 
an initial learning rate of 1e- 4 was used [29]. All our parameters 
were initialized with zero-centered Normal distribution with 
standard deviation 0.02. Training was halted if the model accuracy 
on the validation set decreased twice by more than 0.5%. All of the 
trained models (discussed in the next section) converged before 30 
epochs. 
 
B. Experiment 
 
While the model described above gave us the best results, other 
models were also trained. These models had different hyper-
parameters and filter shapes. However, the training contexts 
remained the same for all the models.  
Initially a baseline CNN with 3 filter layers was trained with 
10 filters in each layer followed by a similar fully connected 
layer (CNN_Base) to get a baseline result. This gave a train 
accuracy of 89.38%. The kernels used had shapes 3x3. Increase 
in the number of layers or filters had no significant 
improvements in performance.  
This could be because of the shape of the filters used. Filters 
with a square shape are not able to capture the larger and more 
spread out relationships between DMRs. Moreover, DNA 
Methylated regions are spread out in the horizontal direction (in our 
image) and a square filter shape may not be able to capture those 
relationships properly.  
Since cancer like diseases are usually not caused by a single 
gene but a subset of genes which could be located far apart on 
the genome, DMRs responsible for regulating such genes would 
also be far apart. Square filters would be efficient in capturing 
changing DMRs when they are located nearby, but may not be 
good in capturing changing DMRs when they are distantly 
located. Hence rectangular filters that can capture changing 
DMR patterns placed near and slightly far were used.  
To test our hypothesis, a rectangular filter was used that 
spanned the entire width of the image with a height of 1 row. 
This gave an improved accuracy. Using a combination of 
filter window sizes of 1, 3, 5 and 7 further improved the 
accuracy (CNN_Width). As discussed previously, this is 
because of how the CpG sites are widely distributed across 
the genome.  
 
 
For further improvements in accuracy height-wise 
convolutional filters was also added that should take into 
account the smaller features in the Methylation patterns that 
are spread out over the entire DNA data. This is the final 
model (CNN_Height_Width).  
 
TABLE II  
COMPARISON OF ACCURACY ON DIFFERENT PARAMETERS OF 
 
ARCHITECTURE 
 
Model Train Accuracy Test Accuracy 
CNN Base 89.38% 84.34% 
CNN Width 95.91% 91.97% 
CNN Height 95.71% 92.06% 
CNN Height Width 96.54% 92.87%  
 
To study the effects of the height-wise filters, a model 
with only height-wise convolutional filters (CNN Height) 
was trained. The result of this shows that there are many 
features that are spread-out in the Methylation data that have 
a correlation with the disease.  
The training results of all the models are tabulated in Table 
II. 
 
V. RESULTS AND DISCUSSION 
 
The aim was to build a model that could learn the minute 
differences of changing DMR patterns on a genome-wide scale and 
generalize well across various cancer types to accurately classify 
the cancer type. The DNA methylation data was evaluated for 32 
cancer types in our experiment. About 10,000 samples was 
examined that represent each of the cancer types to train our model. 
A ’black-box’ approach was taken where the analysis was 
performed on a global scale across entire genomes as opposed to 
targeting specific DNA regions and cancer type. This approach 
allowed the models to capture the changing DMR landscape among 
various cancer types from whole-genome DNA methylation 
datasets. This enabled the model to learn the specific DMR patterns 
within a disease and apply its learning in predicting the cancer type 
from test data that the model has not seen before.  
The proposed model achieves a training accuracy of 96.54% and 
a test accuracy of 92.87%. The accuracy and loss graphs for the 
same have been plotted in figure 3 and figure 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5. Importance scoring of genomic features between two diseases. A) 
BLCA and B) PRAD 
 
 
Further analysis was performed to retrieve the relative 
importance of the ground-level features, genomic regions that are 
collection of CpG sites, which formed the basis for classification of 
diseases in our models. Importance scoring of features in the 
context of this study allows for realizing highly influential genomic 
regions with DMR patterns associated with the diseases. Although 
it is not possible to identify the exact CpG sites that are highly 
influential, since the filters look at a large number of genomic sites, 
importance scoring provides an overview of ability of the model in 
this study in efficiently capturing the changing DMR landscape 
across various diseases from the input.  
Importance scoring of the features comparing two diseases 
(BCLA and PRAD) have been presented in figure 5 as a heat-
map. Scale value for the heat-map is provided to understand the 
relative importance. The scale indicates high to low (top to 
down) importance of features retrieved on a window size 5 for 
both the diseases. Comparing heat-maps in figure 5 reveals that 
albeit very few differences in the important genomic features 
between the two diseases the model is efficiently able to learn 
minute changes in the genomic landscape and apply its learning 
to differentiate between the diseases. Generating more verbose 
visualizations can give us a better understanding of which CpG 
sites may correlate with a certain disease and will be done in a 
future work. 
 
VI. CONCLUSION 
 
Traditional methods to detect cancer are not very efficient. They 
require a lot of manual effort, from sample preparation to detecting 
the disease. Many of these techniques have lower accuracy and 
depend on bio-markers that usually become prevalent in the later 
stages of the disease. Over-diagnosis is also an on-going issue 
whereby false-positives leads to further investigation and adds 
anxiety and financial burden on patients. Hence there is urgent 
requirement to greatly improve the state of cancer screening.  
In comparison to other biochemical techniques, analysis of DNA 
methylation profiles on a whole-genome scale holds significant 
promise in diagnosing cancer with much better precision. However, 
handling large datasets can create roadblocks in efficiently 
analyzing and classifying disease types as the existing methods are 
drastically slow. 
 
 
 
Utilizing deep learning methods gives a major boost to this analysis 
and puts it at an advantage over other methods as deep learning 
methods are not only tailored for processing big datasets but also 
for providing accurate results.  
In this work a CNN based classifier was used to classify diseases 
based on identification of relationship between DNA Methylation 
of specific CpG sites and diseases. In the experiment a model with 
both height-wise and width-wise convolutional filters was trained 
and seen to give the best accuracy.  
The time taken to obtain the results for a batch of 32 test samples 
is 0.35 seconds, whereas the time taken to classify the methylation 
profile for a single test sample is 0.26 seconds (since batching 
improves TensorFlow performance). These values are those 
obtained using TensorFlow run on a system with an Intel i7 
processor with 6 cores and 12 MB of RAM.  
In conclusion the proposed method in this paper can be used in 
classification of cancer type using DNA methylation information 
on a genome-wide scale with high accuracy. Identifying and 
targeting the CpG sites that are responsible for giving rise to the 
condition within each disease could make our approach more 
powerful and achieve top accuracy levels. Finally, we present our 
method to be advanced and highly efficient that can be applicable 
to analyze other epi-genetic related diseases as well, with additional 
parameters for input as required. 
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